CHINA BIOLOGIC PRODS HLDGS I's ticker is CBPO and the CUSIP is G21515104. A total of 72 filers reported holding CHINA BIOLOGIC PRODS HLDGS I in Q1 2019. The put-call ratio across all filers is 0.41 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $2,008,000 | -41.1% | 16,955 | -41.2% | 0.00% | -100.0% |
| Q4 2020 | $3,409,000 | -2.0% | 28,858 | -7.7% | 0.00% | 0.0% |
| Q3 2020 | $3,477,000 | +2.1% | 31,278 | -6.1% | 0.00% | 0.0% |
| Q2 2020 | $3,404,000 | -17.9% | 33,313 | -13.3% | 0.00% | 0.0% |
| Q1 2020 | $4,148,000 | -7.5% | 38,432 | -0.3% | 0.00% | 0.0% |
| Q4 2019 | $4,486,000 | +0.3% | 38,542 | -1.3% | 0.00% | 0.0% |
| Q3 2019 | $4,472,000 | +40.7% | 39,066 | +17.1% | 0.00% | 0.0% |
| Q2 2019 | $3,178,000 | +4.2% | 33,352 | -0.2% | 0.00% | 0.0% |
| Q1 2019 | $3,051,000 | +7.6% | 33,430 | -10.5% | 0.00% | 0.0% |
| Q4 2018 | $2,835,000 | -7.2% | 37,340 | -2.3% | 0.00% | 0.0% |
| Q3 2018 | $3,056,000 | -14.5% | 38,206 | +6.1% | 0.00% | 0.0% |
| Q2 2018 | $3,576,000 | +439.4% | 36,000 | +339.3% | 0.00% | – |
| Q1 2018 | $663,000 | +5.2% | 8,194 | +2.5% | 0.00% | – |
| Q4 2017 | $630,000 | -10.3% | 7,994 | +5.1% | 0.00% | – |
| Q3 2017 | $702,000 | – | 7,609 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Maso Capital Partners Ltd | 143,300 | $11,464,000 | 11.16% |
| Hillhouse Capital Management | 2,751,200 | $220,096,000 | 5.88% |
| York Capital Management Global Advisors, LLC | 1,167,643 | $93,411,000 | 2.95% |
| Kite Lake Capital Management (UK) LLP | 152,836 | $12,227,000 | 2.53% |
| RUDMAN ERROL M | 80,000 | $6,400,000 | 2.39% |
| Dalton Investments, Inc. | 54,551 | $4,364,000 | 2.04% |
| Greenwoods Asset Management Ltd | 245,000 | $19,600,000 | 1.91% |
| Point72 Hong Kong Ltd | 47,296 | $3,784,000 | 1.29% |
| Temasek Holdings (Private) Ltd | 990,000 | $79,200,000 | 0.46% |
| Kassirer Asset Management Corp | 6,000 | $480,000 | 0.32% |